Clinical Trial Overview: Evaluating Zasocitinib for Active Psoriatic Arthritis
Trial Name
LATITUDE-PsA-3002 (TAK-279-PsA-3002): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use.

The Purpose of the Study
Psoriatic Arthritis (PsA) is a chronic inflammatory condition that affects both the joints and the skin. The primary goal of this Phase 3 global study is to evaluate how well an investigational medication called zasocitinib works to reduce joint pain, swelling, and skin symptoms compared to a placebo in adults with active PsA.

What is Zasocitinib (TAK-279)?
Zasocitinib is a highly selective TYK2 (Tyrosine Kinase 2) inhibitor. It works by blocking specific signaling pathways in the immune system that cause the inflammation associated with psoriatic arthritis. Unlike many current PsA treatments that require injections or infusions, zasocitinib is taken as an oral tablet once daily.

Who Can Participate?
You may be eligible to participate if you:

Are an adult (18 years or older) with a confirmed diagnosis of Active Psoriatic Arthritis.

Have active symptoms, such as joint tenderness and swelling, despite your current treatment.

Prior Treatment: This study is open to both those who have never used biologic medicines (“biologic-naïve”) and those who have previously tried biologic treatments for their condition.

What to Expect During the Trial
Study Design: This is a randomized, double-blind, placebo-controlled study. Participants are randomly assigned to receive either the active study drug (zasocitinib) or a placebo.

Treatment Phase: The primary treatment period lasts for 52 weeks.

Transition to Active Drug: After the initial placebo-controlled phase (at Week 16 or 24), participants may have the opportunity to receive the active study drug for the remainder of the 52-week period.

Monitoring: You will visit the study clinic regularly for health assessments, including joint counts, skin evaluations, blood tests, and physical exams to monitor safety and effectiveness.

Long-Term Option: Eligible participants who complete the full 52 weeks may be offered the chance to enter a separate Long-Term Extension (LTE) study.

Why Participate?
By joining this trial, you will receive expert medical monitoring related to your Psoriatic Arthritis and help researchers determine if an oral TYK2 inhibitor can provide a new, effective treatment option for others living with this condition.